Lilly's Rollercoaster: Beats Expectations But CVS Deal Sends Stock Tumbling! Is This The End?

Lilly's Flex: Q1 Earnings Slay!

Okay besties let's get into it! Eli Lilly just dropped their Q1 results and let me tell you they DID. THAT. Revenue shot up 45% to a whopping $12.7 billion – take THAT Wall Street! And adjusted earnings per share? $3.34! I mean *chef's kiss*. It's like when I hit a new Twitch sub record – pure euphoria! They're killin' it with Mounjaro and Zepbound their star GLP 1 meds. But hold up drama's brewing…

CVS and Novo: A Plot Twist No One Asked For

So here's where things get spicy. CVS Health and Novo Nordisk are cozying up and apparently that's got investors PANICKING. CVS is making Wegovy their preferred GLP 1 drug which means Zepbound is getting the boot from their standard formularies. Ouch! It's like when someone unfollows you on Twitter – the betrayal! But honestly is this really 'the end of the world' or are ppl being a little dramatic.

David Ricks: The Calm in the Storm?

CEO David Ricks is out here trying to reassure everyone that Lilly's got this. He's talking innovation better medicines and accessibility. Basically he's saying 'Chill we're not gonna let CVS ruin our glow up!' And tbh I think he makes some valid points. It's like when I try to calm my chat during a heated Valorant match – 'Guys we got this! Focus on the objective!' But the stock market? Not buying it. Shares took a nosedive. Yikes!

Orforglipron: The Secret Weapon?

Lilly's got a secret weapon my friends: orforglipron their oral GLP 1 pill! Apparently it's a game changer. Easier to manufacture ship and store plus some people are scared of needles! Ricks even said 25% of their obesity patients have needle fear. It's like finally finding a dupe for your fave expensive skincare – a total win! Honestly I think this orforglipron thing might be something.

Choice vs. Control: The Real Debate

Ricks isn't happy about CVS limiting choices for doctors and patients. He wants a 'mega category' with lots of options. He even thinks patients will be upset. I mean can you imagine going to your doctor and being told 'Sorry you can't have the medicine that works best for you because CVS said so?' That's some dystopian stuff right there! I stand with Ricks we need options!

Long Term Vision: Diamond Hands Besties!

Despite the CVS drama the analysts at Jim Cramer's Charitable Trust are sticking to their guns. They're reaffirming their $1,000 price target for Lilly and saying their 'long term thesis is unchanged.' They believe Lilly's best in class drugs will keep them growing above the industry average. So basically diamond hands besties! HODL! And maybe just maybe Lilly will pull off another epic comeback. We can only hope.